黄金矿业公司Newmont Corporation (NEM) - 图表显示NEM股价今年以来呈上升趋势，并出现盈利后的跳空上涨 [15] - RSI指标出现负背离，显示股价上涨但内部动能减弱，回调概率较高 [15] - NEM被纳入投资组合中 [15] 科技巨头资金流向 - 早盘交易中资金流入为正的公司包括苹果(AAPL)、亚马逊(AMZN)、谷歌(GOOG)、Meta(META)、微软(MSFT)和特斯拉(TSLA) [5] - 早盘交易中资金流出为负的公司是英伟达(NVDA) [5] - SPDR S&P 500 ETF Trust (SPY)和Invesco QQQ Trust Series 1 (QQQ)资金流向中性 [6] 大宗商品ETF - 最受欢迎的黄金ETF是SPDR Gold Trust (GLD) [7] - 最受欢迎的白银ETF是iShares Silver Trust (SLV) [7] - 最受欢迎的原油ETF是United States Oil ETF (USO) [7] 比特币 - 比特币出现抛售并跌破第一支撑位 [8] 宏观经济数据 - 耐用消费品数据为-9.3%，高于预期的-11% [15] - 扣除运输的耐用消费品数据为0.2%，高于预期的-0.2% [15] - 标普500指数创下自2024年12月以来最长连涨纪录 [15] 投资组合策略 - 传统60/40股债配置在当前环境下不倾向于长期债券配置 [14] - 建议高质量债券或期限不超过5年的债券 [16] - 建议将债券ETF作为战术性而非战略性配置 [16]

Union Pacific Corp. UNP is demonstrating a clear acceleration in its operational and financial performance, fueled by significant productivity gains and a strong earnings beat in its latest quarter. This resurgence, coupled with strategic advancements and a dividend increase, signals a strong trajectory for the rail giant amid evolving market dynamics.Bank of America Securities (BofA) analyst Ken Hoexter reiterated a Buy rating on Union Pacific Corp. and raised the price forecast to $271 from $262, citing g ...

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s GILD Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people who need or want PrEP.Data show that ≥99.9% of participants who received Yeztugo in the Phase 3 PURPOSE 1 and PURPOSE 2 trials remained HIV negative.The first PrEP medication, which was al ...

BP BP stock has been recovering recently from its April lows, along with other major oil and gas companies. This recovery is related to the improvement in oil prices lately. But why should you consider BP stock now?While the stock has not outperformed its peers over the past five years, the company has become a potential takeover target for larger firms. Even if a takeover doesn’t happen, the activist investor Elliott has been building a stake in the company this year, which is something very interesting to ...

公司现状与市场压力 - 公司股价年内下跌14%，而标普500指数上涨8%，市场对其生成式AI战略滞后表示担忧 [1] - 公司是唯一尚未公布明确生成式AI路线图的大型科技企业，落后同行1-2年 [7][11] - 分析师指出iPhone作为核心产品面临创新差距扩大风险，可能威胁公司长期竞争力 [4] 战略转型与投资需求 - 7月31日财报电话会被视为关键节点，需公布大规模生成式AI投资计划以缩小与谷歌、Meta的差距 [2] - 预计资本支出将从2025财年120亿美元增至300-500亿美元/年，用于建设AI数据中心和服务器基础设施 [8] - 可能通过数十亿美元年费协议获取Anthropic等公司的专有模型授权，或收购Perplexity AI（估值140亿美元）加速AI能力 [8][10] 财务与估值挑战 - 公司2026财年前瞻市盈率27.7倍，较10年平均水平17倍溢价63%，较标普500平均22倍高出25% [12] - 当前估值需依赖重大iPhone升级周期支撑，但分析师预计未来12个月内不会出现 [12] - 2025年3月季度数据显示，公司收入增速和利润率扩张速度仅为同行的1/3至1/12 [13] 竞争劣势与结构性问题 - 缺乏自有云平台导致生成式AI成本无法通过外部客户变现，与谷歌云、AWS形成收入模式差距 [14][15] - 竞争对手正构建绕过App Store的生态系统，威胁公司15-30%的应用商店分成收入 [16] - 人才竞争加剧，面临Meta等公司对顶级AI工程师的争夺及现有人才流失风险 [5][9] 运营成本压力 - 预计未来三年需投入数百亿美元于生成式AI，当前市场预期尚未反映这部分成本 [12] - 运营费用将因招聘AI工程师、承担云服务使用成本（依赖第三方）及开发AI工具系统而显著增加 [9] - 维持每年120亿美元资本支出的现状在AI竞争环境中不可持续 [11]

公司业绩表现 - 英特尔第二季度财报表现令人失望，导致股价在周五早盘交易中暴跌9.17%至20.56美元[1][8] - 第二季度营收达到129亿美元，超出市场预期的119.7亿美元，主要受益于客户为避免关税而提前下单[3][5] - 非GAAP毛利率为29.7%，低于市场预期的36.4%[3] 分析师观点 - 美国银行证券认为英特尔营收超预期更多是由于市场对关税影响的保守预期，而非基本面改善[2] - Rosenblatt证券指出管理层对第三季度的营收指引为131亿美元，高于市场预期5亿美元，但毛利率指引36%低于市场预期的37.3%[3] - Benchmark分析师认为英特尔业绩超预期得益于健康的PC市场环境和关税前的订单增加，经调整后每股收益超出市场预期9美分[5] 业务挑战 - 英特尔面临来自AMD和Arm的激烈竞争，且缺乏人工智能产品线[2] - 制造业务资本支出密集，短期内难以改善设计或制造竞争力、市场份额、代工业务或整体财务状况[6] - 公司在数据中心市场份额持续流失，在人工智能领域尚未具备竞争力，14A工艺节点依赖外部客户[8] 未来展望 - 管理层预计第三季度营收将同比下降1.4%，每股收益仅达到盈亏平衡，低于市场预期4美分[4][6] - Needham分析师认为英特尔业绩超预期并上调指引，但关税影响难以量化[7] - 分析师普遍认为英特尔转型需要较长时间，2025年下半年表现可能低于正常季节性水平[8]

On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional marketing authorisation (CMA) for Elevidys (delandistrogene moxeparvovec) for ambulatory individuals aged three to seven years with Duchenne muscular dystrophy (DMD).Sarepta Therapeutics, Inc. SRPT and Roche Holdings AG RHHBY are collaborating to develop and commercialize gene therapy.Also Read: Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revis ...

Edwards Lifesciences Corporation EW reported better-than-expected second-quarter financial results on Thursday.Edwards Lifesciences posted adjusted earnings of 67 cents per share, beating market estimates of 62 cents per share. The company's quarterly sales came in at $1.532 billion versus expectations of $1.488 billion.Edwards Lifesciences affirmed FY2025 adjusted EPS guidance of $2.40-$2.50 and raised FY2025 sales guidance from $5.70 billion-$6.10 billion to $5.90 billion-$6.10 billion.“We are pleased to ...

IMAX Corporation IMAX reported mixed results for the second quarter on Thursday.The company posted quarterly earnings of 26 cents per share which beat the analyst consensus estimate of 21 cents per share. The company reported quarterly sales of $91.68 million which missed the analyst consensus estimate of $92.51 million.“IMAX delivered outstanding financial results in the Second Quarter as the key drivers of our business worked in concert, with strong network growth worldwide, record box office in North Ame ...

Blackstone Inc. BX reported better-than-expected second-quarter financial results on Thursday.The strong performance was fueled by a 25% increase in distributable earnings and robust growth across its key business segments, pushing the firm's total assets under management to a new industry record of over $1.2 trillion.Blackstone reported second-quarter fiscal year segment revenues of $3.075 billion, up 22% Y/Y, beating the analyst consensus estimate of $2.778 billion. Distributable earnings (DE) rose 25% Y/ ...